Targeted Antigens of CAR-T Cell Therapy Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T64969 | Target Info | |||
Target Name | Epidermal growth factor receptor variant III (EGFR vIII) | ||||
Synonyms | ERBB1 variant III; ERBB variant III | ||||
Target Type | Clinical trial Target | ||||
Gene Name | EGFR | ||||
Biochemical Class | Kinase | ||||
UniProt ID |
Targeted Antigens of CAR-T Cell Therapy | Top | ||||
---|---|---|---|---|---|
CAR T-Cell Therapy Drug(s) | Anti-EGFR V III CAR-T cells | Drug Info | Phase 1/2 | Lung cancer | [1] |
Anti-EGFRvIII CAR transduced PBL | Drug Info | Phase 1/2 | Recurrent glioblastoma | [2] | |
Anti-EGFRvIII CAR T cells | Drug Info | Phase 1 | Glioblastoma multiforme | [3] | |
CAR-T cells targeting EGFRviii | Drug Info | Phase 1 | Glioblastoma multiforme | [4] | |
CAR-T Cells targeting EGFRvIII | Drug Info | Phase 1 | Pancreatic cancer | [5] | |
CART-EGFRvIII T cells | Drug Info | Phase 1 | Recurrent glioblastoma | [6] | |
EGFRvIII CAR T cells | Drug Info | Phase 1 | Recurrent glioblastoma | [7] | |
EGFRvIII-CARs | Drug Info | Phase 1 | Recurrent glioblastoma | [8] | |
CART-EGFRvIII T cells | Drug Info | Clinical trial | Glioma | [9] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | ||||
REF 2 | ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health. | ||||
REF 3 | ClinicalTrials.gov (NCT02844062) Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme | ||||
REF 4 | ClinicalTrials.gov (NCT03170141) Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | ||||
REF 5 | ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. | ||||
REF 6 | ClinicalTrials.gov (NCT03726515) CART-EGFRvIII + Pembrolizumab in GBM | ||||
REF 7 | ClinicalTrials.gov (NCT02664363) EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma | ||||
REF 8 | ClinicalTrials.gov (NCT03283631) Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM | ||||
REF 9 | ClinicalTrials.gov (NCT02209376) Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.